Press Release: ZORVOLEX : CORRECTING and REPLACING New Long-Term Safety and Quality of Life Data Reported for ZORVOLEX® in Osteoarthritis Patients

PHILADELPHIA--(BUSINESS WIRE)--The "About ZORVOLEX" boilerplate has been updated as reflected in the text below. The corrected release reads: NEW LONG-TERM SAFETY AND QUALITY OF LIFE DATA REPORTED FOR ZORVOLEX® IN OSTEOARTHRITIS PATIENTS Iroko Presents One-Year Open-Label Phase 3 Data of First Low Dose NSAID at ACR 2014 Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that ZORVOLEX® (diclofenac) capsules was